Adicet Bio, Inc. (ACET)
NASDAQ
Market Cap
$79.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
39 of 963
Rank in Industry
31 of 552
Largest Insider Buys in Sector
ACET Stock Price History Chart
ACET Stock Performance
About Adicet Bio, Inc.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Activity of Adicet Bio, Inc.
Over the last 12 months, insiders at Adicet Bio, Inc. have bought $15M and sold $8,437 worth of Adicet Bio, Inc. stock.
On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $10.89M and sold $4.82M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC () — $322.5M. GORDON CARL L () — $97.5M.
The last purchase of 3,125,000 shares for transaction amount of $7.5M was made by ORBIMED ADVISORS LLC () on 2024‑01‑25.
List of Insider Buy and Sell Transactions, Adicet Bio, Inc.
| 2024-06-05 | Sale | director | 5,900 0.0071% | $1.43 | $8,437 | -2.78% | ||
| 2024-01-25 | 3.13M 7.0488% | $2.40 | $7.5M | -39.68% | ||||
| 2024-01-25 | 3.13M 7.0488% | $2.40 | $7.5M | -39.68% | ||||
| 2023-10-02 | President & CEO | 5,500 0.013% | $1.33 | $7,340 | +15.27% | |||
| 2023-09-29 | Sale | President & CEO | 5,500 0.0127% | $1.36 | $7,481 | +10.22% | ||
| 2023-09-28 | Sale | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +6.34% | ||
| 2023-09-28 | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +6.34% | |||
| 2023-06-30 | director | 5,000 0.0115% | $2.40 | $12,000 | -27.98% | |||
| 2023-06-27 | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | ||||
| 2023-06-27 | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | ||||
| 2023-02-15 | Sale | Chief Technology Officer | 4,533 0.0101% | $7.57 | $34,327 | -67.81% | ||
| 2023-02-10 | Sale | Chief Technology Officer | 10,467 0.0247% | $7.98 | $83,476 | -67.94% | ||
| 2022-11-10 | Sale | President & CEO | 39,955 0.095% | $20.30 | $811,242 | -72.55% | ||
| 2022-11-10 | Sale | Chief Scientific Officer | 6,967 0.0171% | $21.00 | $146,307 | -72.55% | ||
| 2022-11-07 | Sale | President & CEO | 30,000 0.0726% | $19.05 | $571,488 | -69.89% | ||
| 2022-11-03 | Sale | President & CEO | 24,813 0.06% | $18.04 | $447,718 | -68.13% | ||
| 2022-11-02 | Sale | President & CEO | 500 0.0013% | $18.00 | $9,000 | -66.31% | ||
| 2022-10-19 | Sale | Chief Scientific Officer | 8,067 0.0198% | $16.27 | $131,250 | -62.10% | ||
| 2022-10-12 | Sale | Chief Scientific Officer | 1,646 0.0039% | $15.40 | $25,348 | -61.34% | ||
| 2022-09-14 | Sale | President & CEO | 952 0.0023% | $18.00 | $17,136 | -57.90% |
Insider Historical Profitability
<0.0001%
| ORBIMED ADVISORS LLC | 7526359 9.1338% | $0.96 | 3 | 0 | <0.0001% | |
| GORDON CARL L | 7526359 9.1338% | $0.96 | 2 | 0 | <0.0001% | |
| Kauffman Michael | director | 5900 0.0072% | $0.96 | 0 | 1 | |
| SILVERSTEIN JONATHAN | 4830387 5.862% | $0.96 | 1 | 0 | ||
| PureTech Health LLC | 10 percent owner | 2119696 2.5724% | $0.96 | 1 | 6 | |
| Sinclair Andrew | director | 2115385 2.5672% | $0.96 | 1 | 0 | <0.0001% |
| Jakobovits Aya | 356343 0.4324% | $0.96 | 0 | 10 | ||
| Healey Don | Chief Technology Officer | 66568 0.0808% | $0.96 | 0 | 2 | |
| Galimi Francesco | SVP & Chief Medical Officer | 59917 0.0727% | $0.96 | 0 | 1 | |
| Schor Chen | President & CEO | 43469 0.0528% | $0.96 | 5 | 18 | |
| Aftab Blake | Chief Scientific Officer | 28209 0.0342% | $0.96 | 0 | 6 | |
| DUBIN STEVE | director | 10900 0.0132% | $0.96 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| OrbiMed | $26.9M | 13.93 | 11.45M | +37.55% | +$7.34M | 0.21 | |
| RA Capital Management, L.P. | $17.72M | 9.18 | 7.54M | New | +$17.72M | 0.02 | |
| Tang Capital Management, LLC | $15.06M | 7.8 | 6.41M | +631.14% | +$13M | 0.06 | |
| Balyasny Asset Management Llc | $14.53M | 7.52 | 6.18M | New | +$14.53M | 0.04 | |
| RTW Investments, LP | $9.72M | 5.03 | 4.13M | 0% | +$0 | 0.15 | |
| Millennium Management LLC | $9.65M | 5 | 4.11M | +210.7% | +$6.54M | 0.01 | |
| Morgan Stanley | $9.56M | 4.95 | 4.07M | +45.32% | +$2.98M | <0.01 | |
| Goldman Sachs | $9.41M | 4.88 | 4.01M | +13,899.19% | +$9.35M | <0.01 | |
| BlackRock | $7.93M | 4.11 | 3.37M | +54.55% | +$2.8M | <0.0001 | |
| The Vanguard Group | $7.35M | 3.81 | 3.13M | +85.55% | +$3.39M | <0.0001 | |
| The Carlyle Group | $6.9M | 3.59 | 2.95M | +39.39% | +$1.95M | 0.3 | |
| Commodore Capital, LP | $3.23M | 1.67 | 1.37M | New | +$3.23M | 0.01 | |
| Blackstone | $2.91M | 1.51 | 1.24M | New | +$2.91M | 0.01 | |
| Geode Capital Management | $2.83M | 1.47 | 1.2M | +82.08% | +$1.28M | <0.0001 | |
| Schonfeld Group | $2.67M | 1.38 | 1.13M | +466.92% | +$2.2M | 0.02 | |
| Renaissance Technologies | $2.46M | 1.28 | 1.05M | +36.84% | +$663,599.62 | <0.01 | |
| State Street | $2.21M | 1.14 | 940,234 | +46.79% | +$704,273.88 | <0.0001 | |
| Cowen Group | $2.02M | 1.05 | 860,143 | -68.32% | -$4.36M | 0.07 | |
| Octagon Capital Advisors LP | $1.8M | 0.93 | 767,799 | New | +$1.8M | 0.01 | |
| Woodline Partners LP | $1.73M | 0.9 | 735,095 | New | +$1.73M | 0.02 | |
| Alyeska Investment Group L P | $1.54M | 0.8 | 655,665 | New | +$1.54M | 0.01 | |
| DAFNA Capital Management, LLC | $1.41M | 0.73 | 600,000 | New | +$1.41M | 0.03 | |
| Two Sigma | $1.23M | 0.64 | 521,571 | +44.59% | +$377,988.15 | <0.01 | |
| Two Sigma Advisers LP | $1.19M | 0.62 | 506,039 | -2.69% | -$32,900.01 | <0.01 | |
| Northern Trust | $1.02M | 0.53 | 435,615 | +87.7% | +$478,295.85 | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $978,291.00 | 0.51 | 416,294 | New | +$978,291.00 | <0.01 | |
| Nuveen | $964,994.00 | 0.5 | 410,636 | +111.88% | +$509,554.88 | <0.0001 | |
| Johnson & Johnson | $856,509.00 | 0.44 | 364,472 | -47.07% | -$761,688.87 | 0.02 | |
| Acadian Asset Management | $834,000.00 | 0.43 | 355,343 | -36.52% | -$479,748.97 | <0.01 | |
| Silverarc Capital Management Llc | $778,506.00 | 0.4 | 331,279 | New | +$778,506.00 | 0.01 | |
| D. E. Shaw & Co. | $765,980.00 | 0.4 | 325,949 | -5.96% | -$48,574.49 | <0.01 | |
| Atom Investors Lp | $609,371.00 | 0.32 | 259,307 | New | +$609,371.00 | 0.04 | |
| Citadel Advisors LLC | $559,803.00 | 0.29 | 238,214 | +78.8% | +$246,714.79 | <0.0001 | |
| Xtx Topco Ltd | $531,215.00 | 0.28 | 226,049 | +882.78% | +$477,162.66 | 0.01 | |
| Fidelity Investments | $456,372.00 | 0.24 | 194,201 | +42.88% | +$136,974.35 | <0.0001 | |
| Dimensional Fund Advisors | $444,919.00 | 0.23 | 189,327 | +23.41% | +$84,395.65 | <0.0001 | |
| Charles Schwab | $352,679.00 | 0.18 | 150,076 | +116.06% | +$189,447.82 | <0.0001 | |
| BNY Mellon | $343,221.00 | 0.18 | 146,052 | +49.74% | +$114,005.15 | <0.0001 | |
| Stonepine Capital Management Llc | $332,638.00 | 0.17 | 141,548 | New | +$332,638.00 | 0.02 | |
| Exchange Traded Concepts, LLC | $326,634.00 | 0.17 | 138,993 | +69.53% | +$133,966.64 | 0.01 | |
| Bridgeway Capital Management | $305,030.00 | 0.16 | 129,800 | +136.86% | +$176,250.00 | <0.01 | |
| Qube Research & Technologies | $256,716.00 | 0.13 | 109,241 | New | +$256,716.00 | <0.0001 | |
| Prudential Financial | $251,920.00 | 0.13 | 107,200 | +79.72% | +$111,742.50 | <0.0001 | |
| Bank of America | $239,697.00 | 0.12 | 101,999 | +113.64% | +$127,501.25 | <0.0001 | |
| American Century Investments | $145,444.00 | 0.08 | 61,891 | New | +$145,444.00 | <0.0001 | |
| RhumbLine Advisers | $142,157.00 | 0.07 | 60,496 | +28.4% | +$31,443.45 | <0.0001 | |
| JPMorgan Chase | $139,221.00 | 0.07 | 59,243 | +198.75% | +$92,620.52 | <0.0001 | |
| Jane Street Capital | $137,686.00 | 0.07 | 58,590 | +154.61% | +$83,608.00 | <0.0001 | |
| UBS | $125,814.00 | 0.07 | 53,538 | +137.13% | +$72,755.83 | <0.0001 | |
| Cubist Systematic Strategies | $107,992.00 | 0.06 | 45,954 | +135.24% | +$62,084.71 | <0.01 |
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.